Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Decision brief
Answer first · skim in under a minute
Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.
Novartis remibrutinib is now an FDA-approved oral BTK inhibitor for adults with chronic spontaneous urticaria still symptomatic on H1 antihistamines. Phase 3 REMIX-1 and REMIX-2 drove the label, with week-12 UAS7 wins and published 52-week durability data.
Contents10 sections
Key Takeaways
- FDA approved Rhapsido (remibrutinib) on Sept. 30, 2025 for antihistamine-refractory adult CSU.
- REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) used oral remibrutinib 25 mg twice daily versus placebo.
- Primary endpoint: change from baseline in UAS7 at week 12 favored remibrutinib in both Phase 3 trials.
- 52-week data showed sustained UAS7 improvement and a consistent long-term safety profile.
What did Novartis remibrutinib show in Phase 3?
REMIX-1 and REMIX-2 were identical multicenter, double-blind, placebo-controlled Phase 3 trials. Adults with CSU still symptomatic on second-generation H1-antihistamines were randomized 2:1 to remibrutinib 25 mg twice daily or placebo.
The primary end point was change from baseline to week 12 in UAS7 (0–42 scale). Remibrutinib improved the itch-and-hives composite versus placebo. Key secondary measures included UAS7 ≤6 at weeks 2 and 12 and UAS7 of 0 at week 12. See the NEJM REMIX report.
When did the FDA approve Rhapsido?
On Sept. 30, 2025, Novartis announced FDA approval of Rhapsido for adult CSU uncontrolled on H1 antihistamines. The product is an oral tablet taken twice daily and is described as the first FDA-approved BTKi for CSU.
Approval rested on REMIX-1 and REMIX-2 superiority versus placebo on ISS7, HSS7, and UAS7 at week 12. More patients on remibrutinib reached well-controlled disease (UAS7 ≤6) as early as week 2 and at week 12; about one-third had complete absence of itch and hives at week 12, per the PR Newswire approval release.
How durable is the REMIX response?
A 52-week analysis of REMIX-1 and REMIX-2 randomized 470 and 455 patients, respectively. Remibrutinib arms showed sustained mean UAS7 change from baseline near −23 at week 52.
Patients who switched from placebo to remibrutinib at week 24 also improved, with responses seen as early as one week after the switch. Exposure-adjusted adverse-event rates through 52 weeks remained similar to the 24-week analysis, per PubMed 52-week REMIX results.
- REMIX-1: 313 remibrutinib / 157 placebo
- REMIX-2: 300 remibrutinib / 155 placebo
- Dose studied: 25 mg oral twice daily
Label scope and DailyMed indication
DailyMed lists RHAPSIDO (remibrutinib) tablets for CSU in adults who remain symptomatic despite H1 antihistamine treatment. The label states it is not indicated for other forms of urticaria.
That narrow scope matches the REMIX evidence base. Any claim for inducible urticaria or other dermatoses needs separate trials and filings. Label text is on DailyMed RHAPSIDO.
Ongoing head-to-head and age-expansion trials
Novartis is running comparative and expansion studies that matter for positioning. NCT06868212 is a Phase 3 trial of remibrutinib versus dupilumab at early timepoints in adult CSU. NCT06042478 is a Phase 3b study with omalizumab as active control plus an optional 52-week open-label extension.
NCT05677451 enrolls adolescents 12 to under 18 with CSU and inadequate H1 response. NCT06865651 explores mechanism in chronic inducible and spontaneous urticaria. Trial records are on ClinicalTrials.gov NCT05030311 (REMIX-1).
What remains unproven for competitors and payers
Head-to-head outcomes versus dupilumab and omalizumab are not yet public. Relative efficacy, switching rules, and long-term real-world persistence are therefore still open questions for formulary and BD teams watching oral versus injectable CSU options.
Common adverse events in the approval narrative (incidence ≥3%) included nasopharyngitis, bleeding, headache, nausea, and abdominal pain. No lab-monitoring requirement is claimed in the sponsor’s approval materials; clinicians should still follow the full prescribing information and local practice guidelines.
For investors, the near-term signal is commercial uptake in antihistamine-refractory adult CSU, not expansion claims beyond the current label. Pipeline value from adolescent CSU and head-to-head studies remains contingent on future readouts.
Related NovaPharma coverage
- Novartis remibrutinib wins Phase 3 in CSU: what it means
- Remibrutinib drug profile
- Novartis company profile
- Chronic spontaneous urticaria disease hub
Frequently Asked Questions
Is Novartis remibrutinib FDA-approved for CSU?
Yes. On Sept. 30, 2025, the FDA approved Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.
What did the Phase 3 REMIX trials show?
REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) showed remibrutinib 25 mg twice daily beat placebo on weekly urticaria activity (UAS7), itch (ISS7), and hives (HSS7) at week 12.
Does benefit last beyond 12 weeks?
Yes. Published 52-week REMIX follow-up reported sustained UAS7 improvements and a safety profile consistent with the shorter double-blind period.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for remibrutinib.
Unlock full calendar →Novartis pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
